Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer

- Trial to begin enrolling in April; expected primary completion in mid-2027 -

- Primary study endpoint of rate of major pathological response -

Read more at globenewswire.com